InMed Pharmaceuticals Inc. (INM)
INM Stock Price Chart
Explore InMed Pharmaceuticals Inc. interactive price chart. Choose custom timeframes to analyze INM price movements and trends.
INM Company Profile
Discover essential business fundamentals and corporate details for InMed Pharmaceuticals Inc. (INM) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 May 2014
Employees
13.00
Website
https://www.inmedpharma.comCEO
Eric A. Adams Chem.
Description
InMed Pharmaceuticals Inc. operates as a clinical-stage pharmaceutical firm, concentrating its efforts on the investigation and creation of therapeutic solutions derived from cannabinoids. Its primary product, INM-755, is a cannabinol-infused topical cream that is currently progressing through its second Phase I clinical trial for the management of epidermolysis bullosa. Beyond this lead candidate, the company is also developing INM-088, which is undergoing preclinical studies for glaucoma treatment, and INM-405, intended for pain relief. Its broader development pipeline encompasses cannabinoid-based interventions for a variety of medical conditions, with a particular focus on dermatological and ocular disorders. Furthermore, InMed is involved in critical IND-enabling pharmacology and preclinical toxicology research. It is also pioneering IntegraSyn, an innovative integrated biosynthesis approach designed to produce pharmaceutical-grade cannabinoids efficiently. The company maintains a research partnership with BayMedica Inc. to collaborate on the formulation and assessment of novel cannabinoid therapeutics. Established in 1981, the company is headquartered in Vancouver, Canada. It operated under the name Cannabis Technologies Inc. before officially rebranding as InMed Pharmaceuticals Inc. in October 2014.
INM Financial Timeline
Browse a chronological timeline of InMed Pharmaceuticals Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 18 Sept 2026
EPS estimate is -$94.44.
Earnings released on 6 May 2026
EPS came in at -$0.69 surpassing the estimated -$94.44 by +99.27%, while revenue for the quarter reached $1.26m .
Earnings released on 11 Feb 2026
EPS came in at -$0.51 , while revenue for the quarter reached $1.11m .
Earnings released on 6 Nov 2025
EPS came in at -$0.44 , while revenue for the quarter reached $1.12m .
Earnings released on 23 Sept 2025
EPS came in at -$3.80 , while revenue for the quarter reached $1.78m .
Earnings released on 12 May 2025
EPS came in at -$1.94 , while revenue for the quarter reached $1.80m .
Earnings released on 12 Feb 2025
EPS came in at -$3.64 , while revenue for the quarter reached $772.53m .
Earnings released on 14 Nov 2024
EPS came in at -$54.20 , while revenue for the quarter reached $936.16k .
Stock split effective on 14 Nov 2024
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 27 Sept 2024
EPS came in at -$3.80 , while revenue for the quarter reached $938.46k , missing expectations by -47.57%.
Earnings released on 14 May 2024
EPS came in at -$3.60 , while revenue for the quarter reached $863.50k , missing expectations by -51.76%.
Earnings released on 13 Feb 2024
EPS came in at -$3.80 , while revenue for the quarter reached $933.78k , missing expectations by -17.36%.
Earnings released on 14 Nov 2023
EPS came in at -$15.20 , while revenue for the quarter reached $1.25m , missing expectations by -10.07%.
Earnings released on 29 Sept 2023
EPS came in at -$12.92 surpassing the estimated -$85.00 by +84.80%, while revenue for the quarter reached $1.74m , beating expectations by +443.49%.
Earnings released on 15 May 2023
EPS came in at -$12.00 surpassing the estimated -$90.00 by +86.67%, while revenue for the quarter reached $764.09k , beating expectations by +138.03%.
Earnings released on 17 Feb 2023
EPS came in at -$18.20 surpassing the estimated -$90.00 by +79.78%, while revenue for the quarter reached $350.12k , missing expectations by -29.98%.
Earnings released on 11 Nov 2022
EPS came in at -$81.20 surpassing the estimated -$85.00 by +4.47%, while revenue for the quarter reached $234.25k , missing expectations by -53.15%.
Earnings released on 23 Sept 2022
EPS came in at -$258.40 falling short of the estimated -$110.00 by -134.91%, while revenue for the quarter reached $399.63k , missing expectations by -46.72%.
Stock split effective on 7 Sept 2022
Shares were split 1 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 May 2022
EPS came in at -$125.00 falling short of the estimated -$115.00 by -8.70%, while revenue for the quarter reached $247.63k , missing expectations by -20.01%.
Earnings released on 14 Feb 2022
EPS came in at -$155.00 falling short of the estimated -$120.00 by -29.17%, while revenue for the quarter reached $207.89k , beating expectations by +66.31%.
Earnings released on 10 Nov 2021
EPS came in at -$125.00 surpassing the estimated -$175.00 by +28.57%.
Earnings released on 24 Sept 2021
EPS came in at -$205.00 falling short of the estimated -$170.00 by -20.59%.
INM Stock Performance
Access detailed INM performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
